In this review, eight new therapeutic agents marketed in the United States in 2015 are considered: ivabradine, cangrelor, deoxycholic acid, filgrastim-sndz, cholic acid, eluxadoline, parathyroid hormone, and lumacaftor-ivacaftor. Indications and information on dosage and administration for these agents are reviewed, as are the most important pharmacokinetic properties, drug interactions, and other precautions. Practical considerations for the use of these new agents also are discussed. Whenever possible, the properties of the new drugs are compared with those of the older agents marketed for the same indications.
After participating in this activity, the pharmacist will be able to:
- List new therapeutic agents that were approved by the Food and Drug Administration or first marketed during 2015.
- Describe the mechanisms of action and indications for new therapeutic agents.
- Compare and contrast the new therapeutic agents with products available with similar indications.
- Summarize adverse effects and patient safety considerations for new therapeutic agents.
- Discuss important patient education and therapeutic monitoring parameters for new therapeutic agents.
Activity type: Knowledge-based
Learning Level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
To obtain 2.0 contact hours of continuing pharmacy education credit (0.2 CEUs) for completing "New Therapeutic Agents Marketed in 2015: Part 2" complete the CPE examination and evaluation questions. Credit will be awarded upon achieving a passing grade of 70% or better. Please visit CPE Monitor for your transcript.
APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education examination. Please note that you will not be permitted to submit the examination a third time. All exam questions are randomized and may not appear in the same order as printed.
The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the test. Individuals completing this activity by November 1, 2018 can receive credit.
Initial release date: November 1, 2015
Expiration date: November 1, 2018
ACPE Universal Activity Number: 0202-0000-15-182-H01-P
Amy M. Lugo, PharmD, BCPS, BC-ADM, FAPhA
Clinical Pharmacy Specialist with the Defense Health Agency Pharmacy Operations Divisions Formulary Management Branch
DoD Disclaimer: The information discussed here represents the views of the author, and do not necessarily reflect the views of the Department of Defense (DoD), or the Departments of the Army, Navy, and Air Force.
Amy Lugo and APhA's editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete staff disclosures, please see the APhA Accreditation Information section at www.pharmacist.com/education.
"New Therapeutic Agents Marketed in 2015: Part 2” is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association.
There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-15-182-H01-P||0.2 CEUs||November 01, 2015 - November 01, 2018|